1.Incidence of kidney, bladder, and prostate cancers in Korea: An update.
Korean Journal of Urology 2015;56(6):422-428
The incidence of cancer is sharply increasing. Cancer is a leading cause of death as well as a significant burden on society. The incidence of urological cancer has shown a higher than average increase and will become an important concern in the future. Therefore, an overall and accurate understanding of the incidence of urological cancer is essential. In this study, which was based on the Korea National Cancer Incidence Database, annual incident cases, age-standardized incidence rates, annual percentage change (APC), and distribution by age group were examined in kidney, bladder, and prostate cancers, respectively. From 1999 to 2011, the total number of each type of urological cancer was as follows: kidney cancer (32,600 cases, 25.5%), bladder cancer (37,950 cases, 29.7%), and prostate cancer (57,332 cases, 44.8%). The age-standardized incidence rates of prostate cancer showed a significant increase with an APC of 12.3% in males. Kidney cancer gradually increased with an APC of 6.0% for both sexes and became the second most frequent urological cancer after 2008. Bladder cancer showed no significant change with an APC of -0.2% for both sexes and has decreased slightly since 2007. The distribution of kidney cancer according to age showed two peaks in the 50- to 54-year-old and 65- to 69-year-old age groups. Bladder and prostate cancers occurred mostly in the 70- to 74-year-old age group. The proportions of male to female were 2.5:1 in kidney cancer and 5.6:1 in bladder cancer. We have summarized the incidence trends of kidney, bladder, and prostate cancers and have provided useful information for screening and management of these cancers in the future.
Female
;
Humans
;
Incidence
;
Kidney Neoplasms/epidemiology
;
Male
;
Prostatic Neoplasms/epidemiology
;
Republic of Korea/epidemiology
;
Urinary Bladder Neoplasms/epidemiology
;
Urogenital Neoplasms/*epidemiology
2.Clinical characteristics and outcomes in renal transplant recipients with renal cell carcinoma in the native kidney.
In O SUN ; Yu Mi KO ; Eun Young KIM ; Kyung Seon PARK ; Hong Soon JUNG ; Sun Hye KO ; Byung Ha CHUNG ; Bum Soon CHOI ; Cheol Whee PARK ; Yong Soo KIM ; Chul Woo YANG
The Korean Journal of Internal Medicine 2013;28(3):347-351
BACKGROUND/AIMS: We investigated the incidence and clinical characteristics of renal cell carcinoma (RCC) in the native kidney of renal transplant recipients. METHODS: Between 1991 and 2010, 1,425 patients underwent kidney transplantation at our institution. We retrospectively evaluated the clinical features and outcomes in renal transplant patients with RCC in the native kidney after renal transplantation. RESULTS: The patients included three males and two females with a mean age of 63 years (range, 52 to 74). The incidence of RCC was 0.35%. The median interval between renal transplantation and RCC occurrence was 16.2 years (range, 9 to 20). All of our patients with RCC had developed renal cysts either before (n = 3) or after (n = 2) renal transplantation. The mean duration of dialysis was 12 months (range, 2 to 39). Of the five patients, four underwent dialysis treatment for less than 8 months. All the RCCs were low grade at the time of diagnosis. Four patients underwent radical nephrectomy, and one patient refused the operation. The four patients who underwent radical nephrectomy showed no evidence of local recurrence or distant metastasis during the median follow-up of 2.9 years. However, the patient who did not undergo surgery developed spinal metastasis from the RCC 6 years later. CONCLUSIONS: This study suggests that the follow-up period is an important factor for the development of RCC in renal transplant recipients, and more vigorous screening with a longer follow-up period is required in renal transplant recipients.
Aged
;
Carcinoma, Renal Cell/*epidemiology
;
Female
;
Humans
;
Incidence
;
Kidney Neoplasms/*epidemiology
;
*Kidney Transplantation
;
Male
;
Middle Aged
;
Postoperative Complications/*epidemiology
;
Republic of Korea/epidemiology
;
Retrospective Studies
3.Cancer among end-stage renal disease patients on dialysis.
En Yun LOY ; Hui Lin CHOONG ; Khuan Yew CHOW
Annals of the Academy of Medicine, Singapore 2013;42(12):640-645
INTRODUCTIONThe aim of this study is to investigate the risk of cancer among end-stage renal disease (ESRD) patients on dialysis in Singapore.
MATERIALS AND METHODSThe study looks at a retrospective cohort of 5505 ESRD patients who had received dialysis between 1998 and 2007. The cancer risk of these patients would be compared against the risk of the general population.
RESULTSDuring a median follow-up time of 3.9 years, 267 (4.9%) dialysis patients developed cancer. The risk of cancer (excluding non-melanoma skin cancer) is 1.66 times higher in dialysis patients than the general population, and is highest at age less than 35 years old and at first year after dialysis. Cancer risk was found to be significantly higher among Chinese dialysis patients, followed by Malays, compared to the general population. The 3 sites with highest elevated cancer risks among dialysis patients compared to the general population are kidney, tongue and multiple myeloma.
CONCLUSIONThe finding of elevated cancer risk among younger dialysis patients is similar to other international studies. High cancer risks among specific cancer sites were also consistent with other studies. In view of the lack of screening procedures for these cancers and shortened expected survival of ESRD patients, cancer screening of ESRD patients should be individualised and based on a reasonable life expectancy and transplant candidacy, keeping in mind the competing risk of cardiovascular mortality.
Comorbidity ; Humans ; Kidney Failure, Chronic ; epidemiology ; therapy ; Neoplasms ; epidemiology ; Renal Dialysis ; Retrospective Studies ; Risk Assessment ; Singapore ; epidemiology
4.Incidence estimation of genitourinary cancer in Korea.
Chong Wook LEE ; Eun Sik LEE ; Hwang CHOI ; Sung Kun KOH ; Jin Moo LEE ; Soo Eung CHAI ; Byung Kap MIN ; Sung Choon LEE ; Jong Byung YOON ; Young Hee GOH
Journal of Korean Medical Science 1992;7(2):154-161
A nation-wide study was performed to estimate the incidence of bladder, kidney, renal pelvis and ureter, prostate, testicular and other genitourinary cancer among Koreans in Korea using medical records of the inpatients of the beneficiaries of the Korea Medical Insurance Corporation (KMIC) from Jan. 1, 1989 to Dec. 31, 1989. The crude incidence rate of bladder cancer (ICD-9 188) is estimated to be 4.43 and 0.98 per 100,000 in males and females, respectively. Around 1,093 new cases of bladder cancer (895 male and 198 female) are estimated to occur in a year. The adjusted rate for the world population is 7.76 in males and 1.19 in females which is similar to that of Japanese in Osaka and Chinese in Shanghai, but lower than in American whites and blacks. The crude incidence of kidney, renal pelvis and ureteral cancer (ICD-9 189) is estimated to be 1.61 and 0.87 in males and females, respectively. Around 507 new cases of kidney, renal pelvis and ureteral cancer (332 male and 175 female) are estimated to occur in a year. The adjusted rate for the world population is 2.69 in males and 1.04 in females. In the prostate (ICD-9 185), the crude incidence rate of cancer is estimated to be 1.36. Around 274 new cases of prostate cancer are occurring in a year. The adjusted rate for the world population is 2.98 which is similar to the Chinese rate. The incidence of genitourinary cancer continuously increases with age.
Adult
;
Age Factors
;
Aged
;
Carcinoma, Renal Cell/epidemiology
;
Female
;
Humans
;
Incidence
;
Kidney Neoplasms/epidemiology
;
Korea/epidemiology
;
Male
;
Middle Aged
;
Prostatic Neoplasms/epidemiology
;
Sex Factors
;
Urinary Bladder Neoplasms/epidemiology
;
Urogenital Neoplasms/*epidemiology
5.Epidemiology and Treatment Patterns of Urologic Cancers in Korea.
Korean Journal of Urological Oncology 2015;13(2):51-57
Prostate, kidney, and bladder cancers are the three most prevalent urologic cancers in the Korean population. Throughout the last decade, there has been an upsurge in the incidence and prevalence of prostate and kidney cancers, along with a marked improvement in survival. A stage migration has been observed towards early detection of localized cancers, and accordingly, the landscape of urologic cancer treatment in Korea has been characterized by an exponential increase in the number of patients receiving surgery with curative intent. Herein, a substantial proportion of surgeries were performed using minimally-invasive methods, especially robot-assisted surgery. Current management strategies of urologic cancers in Korea are mostly based on evidences provided by international guidelines. There is prompt adoption and clinical application of novel systemic agents for advanced stage cancer, and surgical and oncological outcomes are comparable to those of Western reports. Multidisciplinary treatment options are available for various cancers at different stages. At the same time, treatment decisions are influenced by the availability of health-care resources, which is regulated by the National Health Insurance policy guidelines. Accumulating information on characteristics of urologic cancers in Korean patients demonstrates that Korean patients harbor more aggressive prostate cancer features compared to Western men. Due to the racial disparity in features of certain cancers, the optimal management strategy specific for the Korean population is yet to be validated. A comprehensive national cancer database may help to identify risk factors, select sequential strategies, and to assess survival outcome of Korean urologic cancer patients.
Epidemiology*
;
Humans
;
Incidence
;
Kidney
;
Kidney Neoplasms
;
Korea*
;
Male
;
National Health Programs
;
Prevalence
;
Prostate
;
Prostatic Neoplasms
;
Risk Factors
;
Urinary Bladder Neoplasms
;
Urologic Neoplasms*
6.Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation.
Guang-hua LIU ; Han-zhong LI ; Hui-jun WANG ; Quan-zong MAO ; Ming XIA ; Yi XIE ; Chong XUE ; Hai WANG ; Zhi-gang JI
Acta Academiae Medicinae Sinicae 2009;31(3):288-291
OBJECTIVETo investigate the types and therapies of malignancies in renal allograft recipients.
METHODSWe retrospectively analyzed the occurrence, types, and therapies of malignancies in 498 renal allograft recipients who had received operations in Peking Union Medical College Hospital from May 1986 to October 2008.
RESULTSAmong 498 renal allograft recipients, 18 patients (3.6% ) were diagnosed with malignancies, which included bladder cancer (n = 5), renal pyloric cancer or ureteric cancer (n = 4), leukemia or lymphoma (n = 3), hepatic cancer (n = 2), skin cancer, rectum carcinoma, pulmonary carcinoma and thymoma (n = 1 each). Surgical operations were performed in 10 cases, 6 of whom survived with normal renal function and had no rejection of transplanted kidneys. Three patients with bladder cancer and one patient with ureteric cancer experienced recurrences 7 to 15 months after operations; among them one bladder cancer patient died. One hepatic carcinoma patient died of pulmonary metastasis 8 months after operation. One non-Hodgkin's lymphoma patient died 11 months after chemotherapy. Five cases with advanced unresectable malignancies died 8 to 17 months after the diagnosis.
CONCLUSIONSThe incidences of malignancies, especially urological epithelial carcinoma, are high in renal allograft recipients. Radical surgery of the solid malignancies is a preferred option.
Adult ; Aged ; Female ; Humans ; Kidney Transplantation ; Male ; Middle Aged ; Neoplasms ; epidemiology ; therapy ; Postoperative Complications ; epidemiology ; therapy ; Retrospective Studies
7.The Incidences and Characteristics of Various Cancers in Patients on Dialysis: a Korean Nationwide Study
Soon Kil KWON ; Joung Ho HAN ; Hye Young KIM ; Gilwon KANG ; Minseok KANG ; Yeonkook J KIM ; Jinsoo MIN
Journal of Korean Medical Science 2019;34(25):e176-
BACKGROUND: The numbers of patients on dialysis and their life expectancies are increasing. Reduced renal function is associated with an increased risk of cancer, but the cancer incidence and sites in dialysis patients compared with those of the general population require further investigation. We investigated the incidences of various cancers in dialysis patients in Korea and used national health insurance data to identify cancers that should be screened in dialysis clinics. METHODS: We accessed the Korean National Health Insurance Database and excerpted data using the International Classification of Disease codes for dialysis and malignancies. We included all patients who commenced dialysis between 2004 and 2013 and selected the same number of controls via propensity score matching. RESULTS: A total of 48,315 dialysis patients and controls were evaluated; of these, 2,504 (5.2%) dialysis patients and 2,201 (4.6%) controls developed cancer. The overall cancer risk was 1.54-fold higher in dialysis patients than in controls (adjusted hazard ratio, 1.71; 95% confidence interval, 1.61–1.81). The cancer incidence rate (incidence rate ratio [IRR], 3.27) was especially high in younger dialysis patients (aged 0–29 years). The most common malignancy of end-stage renal disease patients and controls was colorectal cancer. The major primary cancer sites in dialysis patients were liver and stomach, followed by the lung, kidney, and urinary tract. Kidney cancer exhibited the highest IRR (6.75), followed by upper urinary tract (4.00) and skin cancer (3.38). The rates of prostate cancer (0.54) and oropharyngeal cancer (0.72) were lower than those in the general population. CONCLUSION: Dialysis patients exhibited a higher incidence of malignancy than controls. Dialysis patients should be screened in terms of colorectal, liver, lung, kidney and urinary tract malignancies in dialysis clinics.
Colorectal Neoplasms
;
Dialysis
;
Epidemiology
;
Humans
;
Incidence
;
International Classification of Diseases
;
Kidney
;
Kidney Failure, Chronic
;
Kidney Neoplasms
;
Korea
;
Life Expectancy
;
Liver
;
Lung
;
National Health Programs
;
Oropharyngeal Neoplasms
;
Propensity Score
;
Prostatic Neoplasms
;
Renal Dialysis
;
Skin Neoplasms
;
Stomach
;
Urinary Tract
8.Multicentricity and its associated factors in renal cell carcinoma.
Quanlin LI ; Hongwei GUAN ; Qiuping ZHANG ; Jun XUE ; Fapeng WANG ; Xishuang SONG
Chinese Medical Journal 2002;115(9):1341-1344
OBJECTIVETo investigate the incidence and associated factors of multicentricity in renal cell carcinoma (RCC) in Chinese patients.
METHODSOne hundred and two kidney samples from radical nephrectomy due to RCC were step sectioned at 3 mm intervals and examined. All tissue abnormalities were removed, stained and examined for multicentricity. Then, on each slice of the sample, both the parenchymal margin of 15 mm beyond the pseudocapsule and tissue around the renal sinus were continuously sectioned and examined for completeness of the pseudocapsule and vascular and lymph node invasion. The relationship between muliticentricity and other pathological parameters was evaluated.
RESULTSThe incidence of multicentricity was 15.7% (16/102); it was significantly lower in primary tumors < or = 4.0 cm than in tumors > 4.0 cm (4.9%, 2/41 vs 23.0%, 14/61; chi(2) = 6.055, P = 0.014). The incidence was 9.8% (8/82) in tumors without vascular invasion and 40.0% (8/20) in those with it (P = 0.003, Fisher's exact test). The incidence of multicentricity was 1.9% (1/53) in tumors with a complete pseudocapsule and 30.6% (15/49) in those without it (chi(2) = 15.885, P = 0.000). The grade, stage, subtypes and lymph node invasion of the primary tumor were not significantly associated with multicentricity. Multiple logistic regression analysis showed that pseudocapsular incompleteness and vascular invasion were two significant predictors of RCC multicentricity (P = 0.005 and 0.023).
CONCLUSIONSThe incidence of multicentricity of RCC in this group of patients was in accordance with published studies. Multifocality was significantly associated with tumor size, pseudocapsule completeness and vascular invasion. NSS should be limited to tumors less than 4.0 cm when the contralateral kidney is normal and careful long-term follow-up is necessary in tumors with positive vascular invasion and incomplete pseudocapsule.
Aged ; Carcinoma, Renal Cell ; epidemiology ; pathology ; surgery ; China ; epidemiology ; Female ; Humans ; Incidence ; Kidney Neoplasms ; epidemiology ; pathology ; surgery ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Invasiveness
9.Dexmedetomidine can not reduce the incidence of acute and chronic kidney disease after laparoscopic radical nephrectomy: a propensity score matching-based analysis.
Yuwei SU ; Wen SUN ; Di WANG ; Yuyan DONG ; Ying DING ; Longhe XU ; Yongzhe LIU
Journal of Southern Medical University 2023;43(4):654-659
OBJECTIVE:
To investigate the effect of dexmedetomidine (DEX) on renal function after laparoscopic radical nephrectomy.
METHODS:
We reviewed the clinical data of 282 patients with renal cell carcinoma (RCC), who underwent laparoscopic radical nephrectomy (LRN) in the Department of Urology, Third Medical Center of PLA General Hospital from November, 2020 and June, 2022.According to whether DEX was used during the operation, the patients were divided into DEX group and control group, and after propensity score matching, 99 patients were finally enrolled in each group.The incidence of acute kidney injuries were compared between the two groups.Serum creatinine (sCr) data within 3 months to 1 year after the operation were available in 51 patients, including 26 in DEX group and 25 in the control group, and the incidence of chronic kidney disease (CKD) was compared between the two groups.
RESULTS:
After propensity score matching and adjustment for significant covariates, there were no significant differences in postoperative levels of sCr, cystatin C (CysC), β2-microglobulin (β2-MG), hemoglobin (Hb), or C-reactive protein (CRP), extubation time, incidence of AKI, or length of hospital stay between the two groups (P>0.05).The intraoperative urine volume was significantly higher in DEX group than in the control group (P < 0.05).A significant correlation between AKI and CKD was noted in the patients (P < 0.05).The incidence of CKD did not differ significantly between the two groups (P>0.05).
CONCLUSION
DEX can not reduce the incidence of AKI or CKD after LRN.
Humans
;
Dexmedetomidine
;
Incidence
;
Propensity Score
;
Renal Insufficiency, Chronic/epidemiology*
;
Kidney Neoplasms/surgery*
;
Nephrectomy/adverse effects*
;
Laparoscopy/adverse effects*
;
Acute Kidney Injury/prevention & control*
;
Retrospective Studies
10.Risk of Chronic Kidney Disease After Nephrectomy for Renal Cell Carcinoma.
Korean Journal of Urology 2014;55(10):636-642
The incidence of low-stage renal cell carcinoma is rising and is observed to demonstrate excellent prognosis following surgical treatment irrespective of method. However, several epidemiologic observational and population-based studies suggest that radical nephrectomy is associated with increased adverse renal outcomes such as chronic kidney disease (CKD) compared with partial nephrectomy. This is suggested in turn to lead to increased mortality via an increase in cardiovascular complications and mortality. Prospective data are scarce, and there are conflicting data as well on whether surgically induced CKD is as debilitating as medically induced CKD. Further research is needed to assess the presence and the extent of the relationship between nephrectomy, CKD, and noncancer mortality.
Carcinoma, Renal Cell/*surgery
;
Humans
;
Kidney Neoplasms/*surgery
;
Nephrectomy/*adverse effects/methods
;
Renal Insufficiency, Chronic/epidemiology/*etiology
;
Risk Assessment/methods